# Genome Canada

Genome Canada is a Foundation based in Ottawa, Canada.

## Overview

- **Organization type:** Foundation
- **Headquarters:** Ottawa, Canada
- **Region:** North America
- **Address:** Ottawa, ON, Canada
- **Founded:** 2000
- **Assets under management:** Undisclosed
- **Website:** genomecanada.ca
- **LinkedIn:** https://www.linkedin.com/company/genome-canada

## Regulatory record

- **Reports private funds:** No

## About

Genome Canada is based in Ottawa, Ontario. The organization invests in genomic science and technology, translating research into practical applications. Its initiatives span health, agriculture, and environmental sustainability sectors.

## Sectors

- Genomics
- AI/ML
- Digital Health
- AgriTech & FoodTech
- Energy Transition & Renewables

## People

- Rob Annan — President and CEO

## Questions

### What are Genome Canada's current priority investment areas?

The organization's 2021–2027 strategy focuses on three mission pillars: climate resilience and sustainability, advanced health-care delivery through precision medicine, and a bio-based economy leveraging synthetic biology and agricultural genomics. Within these pillars, Genome Canada funds early- to mid-stage research with explicit commercialization pathways. The 2024 launch of the $200 million Canadian Precision Health Initiative signals a deepened commitment to integrating genomic screening into clinical care, moving beyond research into health-system implementation.

### Does Genome Canada take equity positions in the companies it funds?

No. Genome Canada does not take equity and does not operate as a venture investor. Its role is to de-risk genomics-enabled research to the point where private capital — venture firms, corporate venture arms, or pharma partners — can underwrite further development. The organization does track spinoff company formation as a key performance metric and has funded foundational work leading to companies such as Deep Genomics and Chinook Therapeutics, but it exits the commercial stage as grantor, not shareholder.

### Who governs Genome Canada's investment decisions?

Funding decisions are made through independent peer-review panels composed of international scientific experts, commercial leaders, and end-users relevant to each program's focus. The President and CEO, Rob Annan, reports to a board of directors appointed by the federal Minister of Innovation, Science and Industry. The six regional Genome Centres each have their own boards with provincial and local representation, ensuring that portfolio construction reflects national strategy and regional economic priorities simultaneously.

### How is Genome Canada related to the six regional Genome Centres?

Genome Canada is the national coordinating body; the six regional centres — Genome BC, Genome Alberta, Genome Prairie, Ontario Genomics, Génome Québec, and Genome Atlantic — are independent non-profit corporations that administer program funding within their respective jurisdictions. Each centre raises its own provincial and private co-funding and maintains distinct institutional relationships with local universities, health authorities, and industry. This federated structure allows nationally set scientific priorities to adapt to regionally specific economic clusters.

## Related profiles

- [Harman International Industries](https://altss.com/profile/harman-international-industries)
- [Everstream Solutions](https://altss.com/profile/everstream-solutions)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/genome-canada

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology